{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:24:28Z","timestamp":1762917868277},"reference-count":51,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,17]]},"DOI":"10.18632\/oncotarget.25100","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T10:26:56Z","timestamp":1523874416000},"page":"20769-20780","source":"Crossref","is-referenced-by-count":18,"title":["Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma"],"prefix":"10.18632","volume":"9","author":[{"given":"Takuya","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Okuda","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Murase","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Haneda","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Sakane","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"1","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/TCRM.S1603","article-title":"Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma","volume":"4","author":"Goudar","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"3","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant pleural mesothelioma: a population-based study of survival","volume":"5","author":"Zhang","year":"2010","journal-title":"J Thorac Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ctrv.2015.09.006","article-title":"Targeting immune checkpoints: new opportunity for mesothelioma treatment?","volume":"41","author":"Smits","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Lebb\u00e9","year":"2015","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Hotta","year":"2016","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Gainor","year":"2015","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Arrieta","year":"2015","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Gurney","year":"2015","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Savage","year":"2016","journal-title":"Lancet Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Iglesias Docampo","year":"2016","journal-title":"N Engl J Med"},{"key":"13","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor Phase Ib trial: Safety, clinical activity, and PD-L1 expression","volume":"34","author":"Delord","year":"2016","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"van Brummelen","year":"2017","journal-title":"Lancet Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies [OA13.01]","volume":"12","author":"Baas","year":"2017","journal-title":"J Thorac Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jtho.2017.03.018","article-title":"PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?","volume":"12","author":"Galateau-Sall\u00e9","year":"2017","journal-title":"J Thorac Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Averbuch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"18","first-page":"271","volume-title":"Pleural mesothelioma. AJCC Cancer Staging Manual","volume":"26","author":"Trotti","year":"2010","edition":"7th ed."},{"key":"19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Gervais","year":"2016","journal-title":"Lancet"},{"key":"20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"characterization of the anti-PD-1 antibody nivolumab, BMS-936558, andtoxicology in non-human primates","volume":"2","author":"Garner","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)","volume":"10","author":"Felip","year":"2015","journal-title":"PLoS One"},{"key":"23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Lantuejoul","year":"2016","journal-title":"Hum Pathol"},{"key":"24","first-page":"i48","article-title":"Pleural malignant mesotheliomas over express PD-L1","volume":"26","author":"Gatalica","year":"2015","journal-title":"Ann Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations and survival in mesothelioma","volume":"12","author":"Boutros","year":"2017","journal-title":"J Thorac Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Kwon","year":"2014","journal-title":"J Thorac Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Rimm","year":"2014","journal-title":"Lab Invest"},{"key":"28","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","article-title":"Clinical impact of programmed cell death ligand 1 expression in colorectal cancer","volume":"49","author":"Amicarella","year":"2013","journal-title":"Eur J Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Nakanishi","year":"2018","journal-title":"Oncotarget"},{"key":"30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2016.12.006","article-title":"The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma","volume":"104","author":"Maehara","year":"2017","journal-title":"Lung Cancer"},{"key":"31","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with longterm follow-up","volume":"66","author":"Cheville","year":"2006","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Xu","year":"2006","journal-title":"Acta Histochem"},{"key":"33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Anders","year":"2017","journal-title":"JAMA Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Poudenx","year":"2016","journal-title":"Ann Oncol"},{"key":"35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) inthymic epithelial tumors: impact on treatment efficacy and alterationin expression after chemotherapy","volume":"99","author":"Ohe","year":"2016","journal-title":"Lung Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"Rimm","year":"2016","journal-title":"JAMA Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jtho.2016.09.002","article-title":"PD-L1 expression by two complementary diagnostic assays and mRNAhybridization in small cell lung cancer","volume":"12","author":"Zhou","year":"2017","journal-title":"J Thorac Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00000478-200308000-00001","article-title":"The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2559.2003.01583.x","article-title":"Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study","volume":"42","author":"Lonardo","year":"2003","journal-title":"Histopathology"},{"key":"40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Symmans","year":"2015","journal-title":"Ann Oncol"},{"key":"41","unstructured":"VENTANA PD-L1 Assay. Guiding Immunotherapy in NSCLC. Available at http:\/\/www.ventana.com\/documents\/ PD-L1_SP142-NSCLC-Brochure.pdf."},{"key":"42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.athoracsur.2008.10.067","article-title":"Clinical significance of tumorinfiltrating lymphocytes in lung neoplasms","volume":"87","author":"Oliaro","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"43","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1159\/000438523","article-title":"Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis","volume":"37","author":"Jiang","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"44","first-page":"2","article-title":"Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology","volume":"59","author":"Kobayashi","year":"2015","journal-title":"Acta Cytol"},{"key":"45","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.5858\/2005-129-1415-ROHPOD","article-title":"Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies","volume":"129","author":"Allen","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"46","first-page":"347","article-title":"Pathology of diffuse malignant pleural mesothelioma","volume":"9","author":"Corson","year":"1997","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"48","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"He","year":"2016","journal-title":"Lancet"},{"key":"49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial","volume":"389","author":"Polikoff","year":"2017","journal-title":"Lancet"},{"key":"50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","article-title":"Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"11","author":"Walker","year":"2016","journal-title":"Diagn Pathol"},{"key":"51","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/jco.2015.33.15_suppl.8033","article-title":"Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients","volume":"33","author":"Richman","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T18:26:24Z","timestamp":1660933584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":51,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,4,17]]}},"alternative-id":["25100","29755688"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25100","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]}}}